Nano Dimension (NNDM) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
9 Jul, 2026Executive summary
New CFO John Brenton appointed, bringing over 30 years of experience and a focus on operational discipline, effective November 1, 2025.
CEO transition occurred in September, with immediate focus on profitability, revenue growth, and asset maximization.
Strategic alternatives review process is underway, supported by top-tier advisors, with no timeline set for completion.
Significant cost reduction initiatives underway, with non-GAAP operating expenses already 10% below the new baseline.
Net loss from continuing operations increased to $29.5M from $9.9M year-over-year, mainly due to integration and impairment costs.
Financial highlights
Q3 2025 revenue was $26.9M, up 81% year-over-year, driven by Markforged acquisition; standalone revenue (excluding Markforged) was $9.4M, down 37% year-over-year.
Gross profit was $12.7M with an adjusted gross margin of 47.4%, down from 50% last year due to lower revenue and product mix.
Operating expenses were $29.2M, up 29% year-over-year due to Markforged; standalone OPEX decreased 42% year-over-year.
Adjusted EBITDA loss was $16.6M, compared to a $15.3M loss in Q3 2024.
Cash, cash equivalents, and investment securities totaled $515.5M as of September 30, 2025 (down from $551.0M at June 30, 2025).
Outlook and guidance
Q4 2025 revenue expected between $31.5M and $33.5M, representing nearly 21% sequential growth at midpoint.
Non-GAAP gross margin guidance of 47%-48.5% for Q4, reflecting improved operating leverage.
Operating expenses expected between $28M and $29M, with 10%-15% savings targeted versus Q2 baseline.
Adjusted EBITDA loss projected between $12M and $14M, a 22% improvement at midpoint over Q3.
Latest events from Nano Dimension
- Shareholders face a pivotal vote on Board control, with future input on strategic transactions.NNDM
Proxy filing10 Jul 2026 - Record Q2 revenue, improved margins, and a transformative acquisition highlight best quarter.NNDM
Q2 20248 Jul 2026 - Proxy contest seeks board overhaul, annual elections, and more shareholder control over key decisions.NNDM
Proxy filing30 Jun 2026 - Shareholders will vote on strategic direction, governance amendments, and board composition changes.NNDM
Proxy filing29 Jun 2026 - Board supports strategic review and declassification, opposes governance and director changes.NNDM
Proxy filing25 Jun 2026 - Proxy contest aims to declassify the board, restrict poison pills, and replace key directors.NNDM
Proxy filing18 Jun 2026 - Proposed merger with Infinite Epigenetics offers a 20% premium and pivots to AI-powered diagnostics.NNDM
Proxy filing17 Jun 2026 - $890M merger forms a Nasdaq-listed AI diagnostics leader targeting the $90–94B U.S. market.NNDM
M&A announcement16 Jun 2026 - Nano and Infinite plan a merger to create an AI-powered health diagnostics company, pending approvals.NNDM
Proxy filing15 Jun 2026